A Genome-Decoding Research prized at 200 million-pound ($247 million) launches in the United Kingdom. The research based on DNA aims to increase the prevention and treatment of grievous diseases such as cancer and Alzheimer’s. 

Pharma giants GlaxoSmithKline Plc, Johnson & Johnson, AstraZeneca Plc and Amgen Inc., back the inquiry by 100 million pounds.  Analysis and sequence tracking the genetic codes of 500,00 participants at the U.K Biobank, will be part of the initiative.

“In an aging society with an increasing burden of chronic diseases, it is vital that we diagnose earlier, personalize treatment and where possible prevent diseases from occurring altogether. […] This project will help unlock new treatments and grow our understanding of how genetics affects our risk of disease.” said Matt Hancock, Secretary of Health, in a declaration Tuesday.

John Lepore, senior vice president of studies at GSK, said in a distinct declaration, that experimental drugs with genetic backgrounds are twice as probable as others to become novel drugs. The British drug maker said in 2017 that it would partially set aside 40 million pounds for the sequencing project and analyzing information from the first 50,000 respondents.

The DNA code, carried in cells, determines the development of tissues, organs and organisms. From 2006 to 2010 the Biobank, in U.K, hired individuals to provide samples of blood, saliva and urine, as well as comprehensive self-information to match their DNA sequences. According to the government, the “Wellcome Sanger Institute” will reveal data with the outcomes designed to improve the healthcare of the U.K. National Health Service.

After about 13 years of effort, the first project to sequence a single human genome was finished in 2003 for over $2 billion. The cost of decoding a single genome has since dropped to less than $1,000 and can be accomplished in an hour. The U.K. The initiative will lean on Illumina Inc. technology, the DNA sequencing machine manufacturer based in San Diego.

The announcement of the program came together with plans to allow international students to work in the U.K. for two years after their graduation. The government said that will stimulate revealing new discoveries in the science, technology, and research areas.

Source : Bloomberg

Join now

originalgene products


Featured Video

Partner with OriginalGene